A retrospective study from van Rhijn et al19 detected FGFR3 mutations in 77% of pTa, 31% pT1, and 15% of pT2+ urothelial carcinomas, based on 260 tumors. This evidence concerns the gene FGFR3 and urothelial carcinoma.